Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Jahr

2016

Autoren

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Ziemssen T, Compston DA; CARE-MS II Investigators.

Verlag

Neurology. 2016 Nov 8;87(19):1985-1992.

Link

https://doi.org/10.1212%2FWNL.0000000000003319

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Digitale Transformation bei Multipler Sklerose – Fortschritte in Diagnostik, Monitoring und patientenzentrierter Versorgung

Inpatient care for people with multiple sclerosis - a secondary data analysis in Germany between 2019 and 2024

Rethinking EDSS-based ambulation assessment in multiple sclerosis using continuous variable monitoring

Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis

Jump assessment on a force plate—an approach to quantify subtle lower limb neuromuscular deficits in people with multiple sclerosis